Brief: Bioarctic Says Leqembi-Data Suggests Potential To Delay Disease Progression
04/12/2025 07:14
Dec 4 (Reuters) - BioArctic AB BIOAb.ST: NEW LEQEMBI-DATA PRESENTED AT CTAD 2025 SUGGESTS POTENTIAL TO DELAY DISEASE PROGRESSION BY UP TO 8.3 YEARS WITH CONTINUED TREATMENT Source text: ID:nWkr3mnfZJ Further company coverage: BIOAb.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln